Striatal Medium Spiny Neurons In Huntington'S Disease is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Striatal medium spiny neurons (MSNs) are the primary output neurons of the striatum and are severely affected in Huntington's disease. Their degeneration underlies the characteristic motor symptoms of HD.
| Property |
Value |
| Cell Type |
GABAergic Medium Spiny Neurons |
| Location |
Striatum (Caudate and Putamen) |
| Neurotransmitters |
GABA, Substance P, Enkephalin |
| Associated Diseases |
Huntington's Disease |
| Model Systems |
YAC128 mice, HTT knock-in mice, iPSC-derived MSNs |
Medium spiny neurons constitute ~95% of striatal neurons and are the main output of the basal ganglia. Two populations exist:
- D1-MSNs (direct pathway): Express D1 dopamine receptors, project to substantia nigra pars reticulata, facilitate movement
- D2-MSNs (indirect pathway): Express D2 receptors, project to globus pallidus externus, inhibit movement
MSNs integrate cortical, thalamic, and dopaminergic inputs to regulate motor control, habit formation, and reward learning.
- Expanded CAG repeats in the HTT gene produce mutant huntingtin (mHTT) protein
- mHTT forms aggregates in the cytoplasm and nucleus of MSNs [1]
- Toxic gain-of-function and loss-of-normal HTT function both contribute
- Impaired mitochondrial function in MSNs [2]
- Abnormal synaptic plasticity (LTP/LTD deficits)
- Dysregulated transcription (loss of DARPP-32, BDNF)
- Excitotoxicity due to altered glutamate handling
- Striatopallidal neurons (D2-MSNs) are more vulnerable than D1-MSNs
- Indirect pathway degeneration correlates with chorea
- Early loss of substance P-expressing neurons
- Mutant huntingtin interferes with transcription factors (REST, NRSF)
- Loss of BDNF expression impairs neuronal survival
- Decreased DARPP-32 reduces dopamine signaling
- Complex I deficiency in HD striatum
- Impaired calcium handling
- Increased oxidative stress
- mHTT aggregates visible as inclusion bodies
- Proteasome and autophagy impairment
- Sequestration of essential proteins
- Neurotrophic factors (BDNF, GDNF) promote MSN survival
- Mitochondrial protectors (coenzyme Q10, creatine) in clinical trials
- Excitotoxicity modulators (memantine, amantadine)
- HTT allele-specific silencing using antisense oligonucleotides
- CRISPR-based gene editing to correct mutation
- RNA interference to reduce mHTT expression
The study of Striatal Medium Spiny Neurons In Huntington'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- DiFiglia et al., 1997 - Aggregation of huntingtin in neuronal intranuclear inclusions
- Browne et al., 1999 - Mitochondrial respiratory function in Huntington's disease
- Gray et al., 2008 - Targeted disruption of the Huntington's disease gene